
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis is positioned for strong biopharma revenue growth with the adoption of its ImmunoID NeXT platform, Medicare reimbursement wins, and a large addressable MRD market of ~$20 billion. The recent acquisition offer from TEM at a significant premium to the current trading price further validates the potential of Personalis. However, the company's low margins and significant cash burn may lead to a discount in its valuation compared to its peers. Despite potential risks such as slower adoption and increased competition, Personalis' proven track record and strong partners make it an attractive investment opportunity.
Bears say
Personalis is expected to be acquired by Tempus AI in late 2026 or early 2027, which may not be priced at a substantial premium to Thursday's closing price of $15.58, potentially leading to a stagnant stock price and causing concerns about the validity of the deal. Additionally, the company faces execution and focus risks with its commercial partner, Tempus, and volatility in ordering patterns from pharma companies. With a bear case scenario projecting a price target of $6.00 per share, investors should exercise caution when considering investing in Personalis.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares